Warrant
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
HUMA$0.426+7.01%
Humacyte, Inc.
Sector: Biological Products, (No Diagnostic Substances)Industry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$118.34M
Float & O/S:
Inst Own:
DilutionScan read 48 of Humacyte, Inc.'s SEC filings and found 9 warrant series, 1 convertible, 2 ATM programs, 1 equity line, 1 shelf registration and 4 completed offerings on file for HUMA. The latest dilution event on file is ATM sales on Jun 30, 2026. Analysis updated Oct 31, 2026.
Signal8 Summary
HUMA
Going-concern warning from auditors
Snapshot
Humacyte is a small-cap biotechnology company developing bioengineered blood vessels. While the company recently generated its first meaningful revenue ($2.0M in FY 2025) and reported positive Phase 3 trial data, the financial picture is critical.
What's Happening Right Now
- : Humacyte priced a public offering of 47.6 million shares at $1.05 per share to raise roughly $50 million in gross proceeds to extend its cash runway.
- : Humacyte reported positive interim results from a Phase 3 trial, with the ATEV meeting its primary endpoint for female dialysis patients and showing significantly lower infection rates.
- : Symvess is now under contract with the U.S. Department of Veterans Affairs Strategic Acquisition Center, making the product available to 170 VA hospitals.
- : The company filed a 10-Q stating it does not have sufficient liquidity to fund operations beyond one year, raising substantial doubt about its ability to continue as a going concern.
Raise routes on file: effective shelf · latest dilution event 126 days ago
Overall Risk
Offering Ability
Overhead Supply
Historical
Cash Need
AI dilution summary
The dominant contractual driver and its mechanism, then each further driver ranked.
Latest dilution event
Jun 30, 2026 · ATM Sale
Every warrant, convertible, ATM and shelf, cited to the filing
A free account reads 3 tickers a day in full
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
Share count and cash history
Shares outstanding, potential dilution and cash over time
Outstanding
Public Warrants (HUMAW)
Issued 2021
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Private Placement Warrants
Issued 2021
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Issued 2024
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Issued 2024
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
October 2025 RDO Warrants
Issued 2025
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Convertible
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
ATM program
Issued 2022
Total capacity
Sold to date
Remaining capacity
- Sales agent
- Agreement date
- Commission
ATM program
Issued 2025
Total capacity
Sold to date
Remaining capacity
- Sales agent
- Agreement date
- Commission
Equity line
Issued 2024
Commitment
Sold to date
Remaining
- Agreement date
- Term ends
- Discount
S-3 shelf registration
Issued 2025
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
Registered direct offering
Issued 2025
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Offering
Issued 2025
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Registered direct offering
Issued 2026
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Public offering
Issued 2026
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Know who's about to sell into your HUMA trade
Exercise prices, conversion terms, shelf headroom and the filing sentence behind every number.
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
